Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Schramm

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
American Heart Journal|June 7, 2016
Small-vessel treatment with contemporary newer-generation drug-eluting coronary stents in all-comers: Insights from 2-year DUTCH PEERS (TWENTE II) randomized trialLiefke C van der Heijden, Marlies M Kok, Peter W Danse, et al.
Cochlear Implants International|April 28, 2023
Cochlear implant services for children, young people and adults. Quality standardH E Cullington, D Jiang, S J Broomfield, et al.
JACC. Cardiovascular Interventions|May 9, 2020
Thin Composite-Wire-Strut Zotarolimus-Eluting Stents Versus Ultrathin-Strut Sirolimus-Eluting Stents in BIONYX at 2 YearsRosaly A Buiten, Eline H Ploumen, Paolo Zocca, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|September 3, 2015
Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trialLiefke C van der Heijden, Marlies M Kok, Ming Kai Lam, et al.
JACC. Cardiovascular Interventions|March 10, 2018
5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) TrialPaolo Zocca, Marlies M Kok, Kenneth Tandjung, et al.
Lancet (London, England)|November 5, 2013
Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trialClemens von Birgelen, Hanim Sen, Ming Kai Lam, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
American Heart Journal|June 7, 2016
Small-vessel treatment with contemporary newer-generation drug-eluting coronary stents in all-comers: Insights from 2-year DUTCH PEERS (TWENTE II) randomized trialLiefke C van der Heijden, Marlies M Kok, Peter W Danse, et al.
Cochlear Implants International|April 28, 2023
Cochlear implant services for children, young people and adults. Quality standardH E Cullington, D Jiang, S J Broomfield, et al.
JACC. Cardiovascular Interventions|May 9, 2020
Thin Composite-Wire-Strut Zotarolimus-Eluting Stents Versus Ultrathin-Strut Sirolimus-Eluting Stents in BIONYX at 2 YearsRosaly A Buiten, Eline H Ploumen, Paolo Zocca, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|September 3, 2015
Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trialLiefke C van der Heijden, Marlies M Kok, Ming Kai Lam, et al.
JACC. Cardiovascular Interventions|March 10, 2018
5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) TrialPaolo Zocca, Marlies M Kok, Kenneth Tandjung, et al.
Lancet (London, England)|November 5, 2013
Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trialClemens von Birgelen, Hanim Sen, Ming Kai Lam, et al.
Pageof 8